US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder
Refinitiv閱讀少於1分鐘
The U.S. Food and Drug Administration has declined to approve Ultragenyx Pharmaceutical's 
RARE experimental gene therapy to treat a rare genetic disorder, the company said on Friday.
登入或建立一個永久免費帳戶來閱讀此新聞